A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period

Nephrology Dialysis Transplantation

Volumn 21, Issue 5, 2006, Pages 1389-1394

  Formica Jr , Richard N ^a   Friedman, Amy L ^a   Lorber, Marc I ^a   Smith, J Douglas ^a   Eisen, Tom ^a   Bia, Margaret J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II receptor blocker; Calcium channel blocker; Hyperkalaemia; Hypertension; Kidney transplantation

Indexed keywords

ACICLOVIR; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BASILIXIMAB; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; COTRIMOXAZOLE; CREATININE; DIURETIC AGENT; DOXAZOSIN; HEMOGLOBIN; LABETALOL; LOSARTAN; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PREDNISONE; RAPAMYCIN; RENIN; TERAZOSIN; VALGANCICLOVIR;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CADAVER DONOR; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTOSIS; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; BLOOD PRESSURE DETERMINATION; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LOSARTAN; MALE; MIDDLE AGED; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646198401     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk058     Document Type: Article

References (23)

1. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of Mild Hypertension Study: Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724
2. Torregrosa JV, Campistol JM, Montesinos M, Rogada AG, Oppenheimer F, Andreu J. Efficacy of captopril on post-transplant erythrocytosis. Transplantation 1994; 58: 311-314
3. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of post-transplant erythrocytosis: Efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495-500
4. Calvino J, Lens XM, Romero R, Sanchez-Guisande D. Longterm anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000; 15: 82-86
5. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63
6. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46
7. Thomas MC, Cooper ME. Blockade of the renin-angiotensin system: Better late than never. Am J Kidney Dis 2004; 43: 1113-1115
8. Artz MA, Hilbrands LB, Borm G, Assmann GB, Wetzels JFM. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2852-2857
9. Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783-788
10. 1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 [Suppl 1]: 82-86
11. 1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-827
12. Ersoy A, Dilek K, Usta M et al. Angiotensin II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Transplant 2002; 16: 202-205
13. El-Aroundy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-β1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300-306
14. Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787
15. Formica RN, Friedman AL, Lorber MI, Bia MJ. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early post transplant period. Transplantation Proc 2004; 36: 2675-2678
16. Hestin D, Mertes PM, Hubert J et al. Relationship between blood pressure and rennin, angiotensin II and atrial natriuretic factor after renal transplantation. Clin Nephrol 1997; 103: 98-103
17. Kamel KS, Ethier JH, Quaggin S et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1992; 2: 1279-1284
18. Weidekamm C, Hauser P, Hansmann C et al. Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells. Wien Klin Wochenschr 2002; 114: 725
19. Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2003; 284: F955-F965
20. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592
21. Bakris GL, Weir MR. Angiotensin converting enzyme inhibitor associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160: 685-693
22. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817
23. Wang AY, Yu AW, Lam CW et al. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin and insulin like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 2002; 39: 600-608